Shanghai, China

Peilu Li

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Skyline Therapeutics Limited. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peilu Li. Retrieved from https://idiyas.com/inventor/peilu-li-5pimxowd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Peilu Li: Innovator in Gene Therapy

Introduction

Peilu Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of gene therapy, particularly through his innovative work on recombinant adeno-associated viruses.

Latest Patents

Peilu Li holds a patent for a "Recombinant Adeno-Associated Virus with Modified AAV Capsid Polypeptides." This patent represents a crucial advancement in the development of gene therapy techniques.

Career Highlights

Li is currently employed at Skyline Therapeutics Limited, where he continues to push the boundaries of genetic research and therapy. His work is instrumental in the ongoing evolution of treatment methodologies in this vital area of medicine.

Collaborations

Peilu Li collaborates with notable colleagues, including Yanqun Shu and Heping Li, who contribute to his research endeavors and enhance the impact of their collective work.

Conclusion

Peilu Li's innovative contributions to gene therapy and his active role at Skyline Therapeutics Limited highlight his importance in the field. His patent and collaborations reflect a commitment to advancing medical science through innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…